News 03.05.2022 BASEL, Switzerland and ZURICH-SCHLIEREN, Switzerland, May 03, 2022 (GLOBE NEWSWIRE) -- The Swiss Biotech Association and Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Molecular Partners’ Chief Executive Officer Patrick Amstutz, Ph.D.,...
News 28.04.2022 Schlieren (Zurich), Switzerland, April 27, 2022 – Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, today provided a first-quarter business update, showing a significant acceleration in product sales of its Medical devices segment. Medical devices sales increased 102% in Q1 2022 compared to Q1 2021. The U.S....
News 28.04.2022 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Amgen, its collaboration partner for MP0310 (AMG 506), has informed the...
News 21.04.2022 Schlieren (Zurich), Switzerland, April 21, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that its MagnetOs Flex Matrix has been cleared by the U.S. Food and Drug Administration (FDA) as a bone void filler for use in the posterolateral spine. MagnetOs Flex Matrix is...
News 13.04.2022 ZÜRICH, Switzerland, April 13, 2022 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics based on its proprietary antibody-based MHC-targeting T cell engager technology, today announced the closing of a $76 million Series A financing led by Jeito Capital and...